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The effects of arginine, homoarginine, a-keto-&guanidinovaleric acid and argininic acid (guanidino compounds that were found to 
be increased in hyperargininemia) were evaluated on responses to y-aminoburtyric acid (GABA) and glycine (Gly) on mouse neurons 
in primary dissociated cell culture. GABA and Gly were applied iontophoretically and intracellular microelectrode recording tech- 
niques were used. 
The guanidino compounds rapidly and reversibly inhibited both GABA and Gly responses. The guanidino compounds inhibited 
GABA responses in a concentration-dependent manner and inhibited Gly responses at a concentration of 10 mM. Argininic acid was 
the most potent in reducing inhibitory amino acid responses, followed in decreasing potency by a-keto-&guanidinovaleric acid, ho- 
moarginine and arginine. The guanidino compounds were equally potent in decreasing Gly and GABA responses. Co-application of 
CGS 9896, a benzodiazepine receptor antagonist, did not antagonize the guanidino compound-induced inhibition of GABA re- 
sponses. These findings suggest that the guanidino compounds inhibited responses to the inhibitory neurotransmitters GABA and Gly 
by blocking the chloride channel. This effect might underlie the in vivo epileptogenicity of some of the guanidino compounds and 
might contribute to the pathogenesis of seizures in hyperargininemia. 
INTRODUCTION 
Hyperargininemia is a rare inborn error of me- 
tabolism and is characterized by a deficiency of ar- 
ginase, the last enzyme of the urea cycle, which 
converts arginine to urea and ornithine. The first 
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clinical and biochemical descriptions date from 
1969 and 197d7-39. At present, hyperargininemia 
has been diagnosed in at least 32 children of 27 
kindreds scattered all over the wor1d’,3,4,9,‘2,13, 
20~21~27~28~31~35~36~40~42. The disease is autosomal reces- 
sive and a variety of neurological complications 
have been reported including mental deteriora- 
tion, progressive spasticity and seizures which are 
not temporally related to hyperammonemia. 
The hyperammonemia is not persistent and is 
less pronounced than in other urea cycle disorders 
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and even absent in certain hyperargininemia pa- 
tients. It has been suggested that ammonia is not 
the sole toxic agent in this disease, but that argi- 
nine and/or its metabolites, the guanidino com- 
pounds, might contribute to at least some of the 
neurological complications of this disease. Indeed, 
several guanidino compounds, some of which 
were previously shown to be experimental convul- 
sants, were found to consistently accumulate in 
biological fluids of hyperargininemic patients”*‘*. 
As a consequence of the arginase deficiency, the 
serum and cerebrospinal fluid (CSF) arginine and 
homoarginine levels are increased in hyperargin- 
inemia. Analytical results indicate that the second- 
ary catabolic pathway of arginine, which is .most 
activated in this disease, involves transamination 
with the formation of a-keto-&guanidinovaleric 
acid. Moreover, the reduction of a-keto-d-guani- 
dinovaleric acid with the formation of argininic 
acid was also shown to be pronounced (see Fig. 1). 
Activation of this secondary pathway results in in- 
creased serum and CSF concentrations of a-keto- 
d-guanidinovaleric acid and argininic acid. Both a- 
keto-6-guanidinovaleric acid and homoarginine 
were shown experimentally to be convulsant after 
topical application to the rabbit and rat sensory- 
motor cortex’6,41. To our knowledge, the epilepto- 
genicity of argininic acid has not been studied. Ar- 
ginine did not alter the electroencephalogram af- 
ter application to the sensory-motor cortex in rab- 
bits at a concentration of 0.1 M16. 
A reduction in central nervous system GABAer- 
gic inhibition has been suggested to be a cause of 
epi]epsy14319,24J0. Several convulsants, including 
bicuculline, picrotoxin, penicillin, d-tubocurarine 
and pentylenetetrazol, have been shown to be 
GABA receptor antagonists, blocking the inhibi- 
tory action of GABA by interacting with either the 
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GABA or picrotoxin binding sites8p15,23*25,32. Ben- 
zodiazepine receptor ligands which were convul- 
sant or proconvulsant, such as the &carbolines, /l- 
CCM, #KCE and DMCM, and the pyrazoloquin- 
oline, CGS 8216, reduced GABAergic inhibition 
through an allosteric interaction with the GABA, 
receptor2,5,8.‘1,26,34. Previously, a-keto-d-guanidi- 
novaleric acid was shown to inhibit GABA and 
Gly responses, probably by blocking their chloride 
channels’. 
In an attempt to determine the mechanisms 
through which arginine , homoarginine and arginic 
acid might contribute to development of seizures 
in hyperargininemia, we evaluated the effects of 
these guanidino compounds on responses evoked 
by iontophoretically applied GABA and Gly re- 
corded from spinal cord neurons in cell culture. 
METHODS 
Primary dissociated cell culture 
Spinal cord neuron cultures were prepared from 
dissected spinal cords and attached dorsal root 
ganglia from 12-14-day-old fetal mice as de- 
scribed previouslf9. The tissue was minced and 
then mechanically dissociated by trituration in 
Ca2+- and M2+-free balanced salt solution to a 
suspension of single cells and small clumps. The 
dissociated cells were suspended in culture medi- 
um (90% Eagle’s minimal essential medium sup- 
plemented with 5.5 g/l of glucose and 1.5 g/l of 
NaHCO,, 5% heat-inactivated horse serum and 
5% Nu-Serum II (Collaborative Research Inc.) 
(325 mOsmo1) and then plated on sterile collagen- 
coated 35 mm dishes. The cultures were main- 
tained in an incubator with an atmosphere of 93% 
room air and 7% CO, at 35 “C. The bicarbonate/ 
CO, buffer maintained pH at 7.4. 5-Fluoro- 
arginine 
H/, 
ornithins + urea 
P 
tr0n8omlnotlon hydrogwtotion 
arginine Y a-krto--f-guanidino- * argininic 
valeric acid acid 
Fig. 1. Arginase deficiency results in the activation of secondary catabolic pathways. 
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2’-deoxyuridine was added to the cultures on days 
6-8 to suppress the growth of rapidly dividing non- 
neuronal cells. Medium was changed twice week- 
ly. Cultures were maint~ned for 4-9 weeks before 
electrophysiological experiments. 
Experimental procedures 
Solutions. AI1 recordings were made in a Dul- 
becco’s phosphate-buffeted saline (DPBS) after 
removal of growth medium. The DPBS, with ele- 
vated magnesium ion concentration in order to 
suppress spontaneous activity, contained (in mM): 
NaCl, 137; Na,HPO,, 8.06; ISCI, 2.68; KH,PO,, 
1.47; CaCl,, 1; MgCl,, 10; glucose, 5.6 (pH 7.3- 
7.4}. Heavy paraffin oil was applied to the surface 
of the bathing solution to retard evaporation. So- 
lutions of drugs were prepared on the day of the 
experiment in the following manner: arginine hy- 
drochloride, homoarginine hydrochloride, a-keto- 
~-guanidinovaleric acid and argininic acid were 
dissolved in DPBS to form 10 mM solutions. Ali- 
quots were removed and diluted in bathing medi- 
um to obtain the applied solutions. For the study of 
the influence of the guanidino compounds on 
GABA responses, arginine, homoarg~ine, a- 
keto-&guanidinovaleric acid and argininic acid 
were all applied at 1 and 10 mM. In addition, a- 
keto-&guanidinovaleric acid and argininic acid 
were applied at 100pM. The effects of the guanid- 
ino compounds on Gly responses were evaluated 
at a concentration of 10 mM. CGS 9896, a pyrazo- 
loquinoline previously shown to be a pure benzo- 
diazepine receptor antagonist’, was dissolved in 
dimethylsulfoxide to obtain a 10 mM stock solu- 
tion. Aliquots were removed and diluted in bath- 
ing medium to obtain the applied concentration 
containing less than 0.1% of dimethylsulfoxide. 
Experimental apparatus. For experiments, the 
culture dish containing the bathing solution was 
placed on a stage with temperature regulated at 
34-35 “C. The stage was mounted on a Leitz in- 
verted microscope fitted with phase-contrast op- 
tics to facilitate micropipette placement (using 
Leitz micromanipulators) and to penetrate cells 
under direct visual control. 
~~ec~op~ysioZogica1 recordings. Intracellular 
recordings were made from the somata of spinal 
cord neurons (>20 pm) using glass micropipettes 
(20-25 MQ) filled with 3 M KCl. Use of an active 
bridge circuit (Dagan 8100 or W-P Instruments 
M707) allowed simultaneous recording of mem- 
brane potential and injection of current (for 
steady-state polarization or periodic stimulation) 
using a single micropipette. The preamplifier out- 
put was led to a 6-channel polygraph (Gould 
2600s) for continuous recording. 
GABA and Gly responses. GABA (0.5 M, pH 
3.4) and Gly (0.5 M, pH 3.0) were applied ionto- 
phoretically using 500 ms duration rectangular 
current pulses at 5 s intervals. Iontophoretic pip- 
ettes were positioned to within 2 pm of neuronal 
somata. The use of 3 M KCl-filled micropipettes 
shifted the chloride equilibrium potential from 
about -65 mV to about -20 mV. Under these con- 
ditions, an increase of chloride conductance re- 
suited in an outward chloride current, giving depo- 
larizing GABA and Gly responses”. Responses of 
about lo-15 mV in amplitude were evoked follow- 
ing membrane hyperpolarization (-70 to -90 mV) 
to avoid saturation at or near the chloride equilib- 
rium potential. Effects on GABA and Gly re- 
sponses were accepted only if the responses re- 
turned to control amplitude within 5 min of remov- 
al of the drug-containing micropipette. 
Drug application. The tested guanidino com- 
pounds were applied by local superfusion. A 
blunt-tipped (5- 10 ym) pipette filied with the test 
solution was positioned 15-30 pm from the soma 
of the cell under study. The open end of the local 
superfusion pipette was connected to a pressure 
regulator, set between 0.4 and 0.8 pounds per 
square inch (psi), by tight-fitting polyethylene tub- 
ing. Pressure pulse duration, regulated by a volt- 
age-activated 3-way valve, was 10 s. Under these 
conditions, local superfusion produced no arti- 
facts, and application of control solution (DPBS 
alone) was free of significant effects. When study- 
ing the effect of co-application of the guanidino 
compounds and the benzodi~epine receptor an- 
tagonist CGS 9896, the drugs were applied 
through one local superfusion pipette to avoid flow 
artifacts. As a control, DPBS alone applied by dif- 
fusion was without effect in this paradigm. The lo- 
cal superfusion pipettes and recording micro- 
pipettes were held by Leitz micromanipulators. To 
decrease leakage of drugs into bathing medium, 
the tips of the local superfusion pipettes were kept 
in the oil phase between drug application trials. 
They were lowered into the aqueous phase only 
when drug application was desired. 
Drugs. GABA, Gly and the guanidino com- 
pounds arginine , homoarginine and argininic acid 
were purchased from Sigma Chemical Company 
(St. Louis, MO, U.S.A.) a-keto-&guanidinova- 
leric acid was synthesized enzymatically’. Struc- 
tural formulas of the studied guanidino com- 
pounds are shown in Fig. 2. CGS 9896 (2-(4chloro- 
phenyl)-2,5-dihydropyrazolo-(4,3-C) quinoline3 
(3-H)-one) was obtained from Ciba-Geigy Corp. 
(Summit, NJ, U.S.A.). 
Algebraic and statistical methods. At all applied 
concentrations, mean values and standard devia- 
tions were calculated for the obtained amplitudes 
of the GABA and Gly responses. The responses 
obtained during local superfusion of the tested 
drugs were expressed as percentage of the control 
responses. The statistical significance of differ- 
ences between GABA and Gly responses with and 
without drug application was calculated using the 
2-tailed Student’s t-test; P < 0.05 was considered 
statistically significant. 
RESULTS 
Direct effects of arginine, homoarginine, a-keto-d- 
guanidinovaleric acid, argininic acid and CGS 
9896 on GA BA responses 
Application of arginine and homoarginine at 1 
ARGININE 









Effects of arginine (Arg), homoarginine (HArg), a-keto-d- 
guanidinovaleric acid (a-k-&GVA) and argininic acid (ArgA) 
on mouse spinal cord neurons 
Number GA BA responses 
of cells % of control 
studied (mean + S. D.) 
4 1mM 5 101 f 3.54 
10mM 5 49.3 f 7.02** 
HArg 1mM 7 98.0 f. 1.88* 
10mM 6 38.7 + 12.9** 
a-k-&GVA 100,~M 6 96.4 + 2.94** 
1mM 6 51.0 + 7.62** 
10mM 6 13.6 + 8.24** 
ArgA 1OOpM 6 95.8 + 2.30** 
ImM 5 45.0 + 5.03** 
10mM 5 0.00 + o.OO** 
*P < 0.05; **P < 0.01 compared to controls. 
and 10 mM and a-keto-&guanidinovaleric acid 
and argininic acid at lOOpM, 1 mM and 10 mM did 
not alter resting membrane potential or conduc- 
tance. Application of recording solution (n = 16) 
did not significantly alter GABA responses (0.1 + 
1.7%). Application of CGS 9896 1 PM (n = 11) 
was free of significant effects on GABA responses 
(0.23 5 4.36% increase). Arginine, homoargin- 
ine, a-keto-&guanidinovaleric acid and argininic 
acid rapidly and reversibly reduced GABA-re- 
sponses in a concentration-dependent manner 
NH,- C - 
II 
NH 
NH,- C - 
II 
NH 




NH - (CH,),- CH - COOH 
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OH 
Fig. 2. Structural formulas of arginine, homoarginine, a-keto-&guanidinovaleric acid and argininic acid. 




Fig. 3. Reversible, concentration-dependent effects of arginine 
(ARG) (A), homoar~nine (HARG) (B), a-keto-~-guanidino- 
valeric acid (a-k-6-GVA) (C) and argininic acid (ARGA) (D) 
on GABA responses. PRE shows stable GABA responses be- 
fore drug application. The 2 middle responses show the effect 
of the superfused drug. GABA responses returned to control 
values (POST) within 2 min following removal of the guanidino 
compound-containing micropipette. Iontophoretic application 
of GABA is indicated with a dash. 
(Fig. 3 and Table I). While arginine was devoid of 
any significant effect on GABA responses at 1 
mM, it significantly decreased GABA responses 
to 49.3 i: 7.02% of control values at 10 mM. Ho- 
moarginine, a-keto-Sguanidinovaleric acid and 
argininic acid, at all applied concentrations, sig- 
nificantly reduced GABA responses. Argininic 
acid completely inhibited GABA responses at 10 
mM. Argininic acid was the most potent drug in in- 
hibiting GABA responses, followed, in decreasing 
TABLE II 
Effects of Arg, HArg, a-k-6-GVA and ArgA on Gly responses 




Arg 10mM 7 
HArg 10mM 4 
a-k-a-GVA 10mM 8 
ArgA 10mM 6 
Giy responses 
% of control 
(mean + S. D.) 
-. 45.2 t 7.12** 
21.1 i 13.4** 
27.2 t 32.5** 
7.52 _+ 15.0** 
**P < 0.01 compared to controls. 
potency, by a-keto-~-guanidinovaleric acid, ho- 
moarginine and arginine . 
Direct effects of arginine, homoarginine, a-keto-S- 
guanidinovaferic acid and argininic acid on Gly re- 
sponses 
Arginine (10 mM) and argininic acid (10 mM) 
rapidly and reversibly decreased Gly responses 
(Fig. 4 and Table II). The guanidino compounds 
TABLE III 
CGS 9896, a benrodiazepine receptor antagonist, did not infiu- 
ence the effects of Arg, HArg, a-k-b-GVA and ArgA on GABA 
responses on mouse spinal cord neurons 
Number of GABA responses 
cells % ofcontrol 
studied (mean i S. D.) 
CGS 9896 1 PM 
Arg 10 mIvf 
Arg 10 mM 
+ CGS 9896 1 PM 
HArg 10 mM 
HArg 10 mM 
+ CGS 9896 1 PM 
a-k-&GVA 10 mM 
a-k-d-GVA 10 mM 
+ CGS 9896 1 PM 
ArgA 10 mM 
ArgA 10 mM 
+ CGS 9896 1 j&f 
11 100 i 4.36 
3 45.5 t 10.9 
3 48.0 t 10.6 
3 34.4 * 10.9 
3 39.0 -t 9.50 
3 18.5 t 11.6 
3 18.5 f 10.0 
3 0.00 + 0.00 
3 0.00 + 0.00 
No statistical differences were found for the paired samples (in- 
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Fig. 4. Reversible effects of arginine (10 mM) (A), homoarginine (10 mM) (B), a-keto-&guanidinovaleric acid (10 mM) (C) and 
argininic acid (10 mM) (D) on Gly responses on spinal cord neurons. PRE shows stable Gly responses before drug application. The 
middle responses shows the effect of the superfused drug. Gly responses returned to control values (POST) within 2 min following re- 
moval of the guanidino compound-containing micropipette. Iontophoretic application of Gly is indicated with a dash. 
were equally effective in decreasing Gly and 
GABA responses. 
Effects of co-application of arginine, homoargi- 
nine, a-keto-d-guanidinovaleric acid and argininic 
acid with CGS 9896 on GABA responses 
The effects of arginine (10 mM), homoarginine 
(10 mM), a-keto-&guanidinovaleric acid (10 mM) 
and argininic acid (10 mM) alone or in combina- 
tion with CGS 9896 (1 PM), a benzodiazepine re- 
ceptor antagonist, were not significantly different 
(Table III). 
DISCUSSION 
We have studied the effects of 4 guanidino com- 
pounds that were found to be increased in cerebro- 
spinal fluid of hyperargininemia patients on re- 
sponses to the iontophoretically applied inhibitory 
neurotransmitters GABA and Gly on mouse neu- 
rons in primary dissociated cell culture. The guan- 
idino compounds were arginine, homoarginine, a- 
keto-&guanidinovaleric acid and argininic acid. 
Arginine, homoarginine, a-keto-&guanidinova- 
leric acid and argininic acid inhibited GABA re- 
sponses on mouse spinal cord neurons in cell cul- 
ture in a concentration-dependent manner and in- 
hibited Gly responses at a concentration of 10 
mM. Argininic acid was the most potent in in- 
hibiting responses to inhibitory amino acids, fol- 
lowed in decreasing potency by a-keto-6-guanidi- 
novaleric acid, homoarginine and arginine. The 
observed inhibition of GABA responses was not 
mediated through the benzodiazepine receptor: 
CGS 9896, a pyrazoloquinoline and benzodiaze- 
pine receptor antagonis?, did not antagonize the 
guanidino compound-induced inhibition of 
GABA responses. Earlier studies on neurons in 
culture demonstrated that the inhibitory neuro- 
transmitters GABA and Gly act through different 
receptors on the membrane surface”,29. More- 
over, activation of chloride conductance has been 
demonstrated to underlie the GABA and Gly re- 
ceptor-coupled events. Since GABA and Gly 
exert their inhibitory effects by activation of chlor- 
ide conductance through interaction with different 
receptors, our observations suggest that arginine, 
homoarginine, a-keto-&guanidinovaleric acid 
and argininic acid, shown here not to be benzodi- 
azepine receptor ligands, inhibit inhibitory amino 
acid-responses by blocking chloride channels. 
Although only observed at concentrations 
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higher than those hitherto found in cerebrospinal 
fluid, the inhibitory effects of arginine, homoargi- 
nine, a-keto-~-guanidinovaleric acid and argininic 
acid on inhibitory neurotransmitter responses 
might have pathophysiological importance. In- 
deed, when evaluating the possible neurotoxicity 
of a given compound, one should take into account 
the possibility of an increased susceptibility of the 
diseased subject as well as the possible accumula- 
tion of the substance in brain tissue. Moreover, the 
studied guanidino compounds might have, per- 
haps in combination with still other toxins, addi- 
tive effects. Two guanidino compounds found to 
accumulate in CSF of uremic patient8, guanidine 
and methylguanidine, had an additive inhibitory 
effect on responses to the inhibitory neurotrans- 
mitters GABA and Gly (DeDeyn and Macdonald, 
unpublished observations). An additive effect has 
also been shown for creatinine, creatine, guanidi- 
noacetic acid and guanidine in an experimental 
paradigm testing in vitro autohemolysis”. Earlier 
reports demonstrated a-keto-&guanidinovaleric 
acid16 to be more potent than homoarginine4* in in- 
ducing seizures in rabbit and rat, respectively. 
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